Table 4.
Characteristics and prognosis of IBD patients: EBV-DNA positive and EBV-DNA negative in blood, EBER-1 positive and EBER-1 negative in mucosa
| EB-DNA loading in blood |
EBER-1 concentration in mucosa |
|||||
|---|---|---|---|---|---|---|
| Low EB-DNA loading (n=31) | High EB-DNA loading (n=17) | P | Low EBER-1 concentration (n=16) | High EBER-1 concentration (n=11) | P | |
| Age, (mean±SD) (years) | 45.19±19.2 | 51.29±12.9 | 0.316 | 49.33±18.6 | 52.72±15.5 | 0.721 |
| Sex, male/female, n | 26/5 | 11/6 | 0.131 | 10/6 | 9/2 | 0.280 |
| UC/CD, n | 18/13 | 10/7 | 0.959 | 10/6 | 9/2 | 0.280 |
| Refractory, n (%) | 16 (19.4%) | 7 (41.2%) | 0.489 | 8 (50.0%) | 11 (100.0%) | 0.005 |
| Clinical disease activities*, n (%) | ||||||
| Mild | 0 (0.0%) | 0 (0.0%) | - | 0 | 0 | - |
| Moderate | 10 (32.3%) | 5 (29.4%) | 0.839 | 5 (31.3%) | 4 (36.4%) | 0.782 |
| Severe | 21 (67.7%) | 12 (70.6%) | 0.839 | 11 (68.8%) | 7 (63.7%) | 0.782 |
| The degree of intestinal mucositis, n (%) | ||||||
| Mild | 1 (3.2%) | 0 (0.0%) | 0.454 | 0 (0.0%) | 0 (0.0%) | - |
| Moderate | 12 (38.7%) | 6 (35.3%) | 0.815 | 9 (56.3%) | 1 (9.1%) | 0.013 |
| Severe | 18 (58.1%) | 11 (64.7%) | 0.653 | 7 (43.8%) | 10 (90.9%) | 0.013 |
| Clinical remission within 3 months, n (%) | 22 (80.0%) | 12 (70.6%) | 0.978 | 12 (75.0%) | 5 (45.5%) | 0.118 |
| Surgery within 3 months, n (%) | 5 (16.1%) | 3 (17.6%) | 0.893 | 3 (18.8%) | 3 (27.3%) | 0.601 |
| Lymphoma was observed during follow-up, n (%) | 0 (0.0%) | 1 (5.8%) | 0.172 | 0 (0.0%) | 1 (9.1%) | 0.219 |
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; EBV, Epstein-Barr virus; EBER-1, Epstein-Barr virus-encoded small-RNA 1. *Clinical disease activities: the Mayo Clinic score for ulcerative colitis (UC) and Crohn’s disease activity index for Crohn’s disease (CD). OR, Odds ratio; CI, confidence interval.